Drugs / NW300EMCBD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07186283 | Sep → Dec 2025 | — | NW PharmaTech Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NW300EMCBD | “Regimen A: 600 mg of the new CBD formulation (NW300EMCBD) administered orally” NCT07186283 ↗ |
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07186283 ↗ |
| Route | Oral | “administered orally” NCT07186283 ↗ |